Summary
The relationship between the presence of the c-erbB-2 protein, demonstrated immunohistochemically with antibody 21N, and thymidine labelling index (TLI) has been studied in thein situ component of 70 cases of carcinoma of the breast. A significant association was found between high TLI and positive staining. Twenty of the 70 cases stained (29%) and of those that were stained 75% had a high TLI; 43% of those with a high TLI stained positively but only 14% of those with a low TLI stained positively. Strong correlations were seen between nuclear size and histological pattern and both 21N staining and TLI. The majority of carcinomas of comedo pattern with large nuclei were 21N positive and had a high TLI, whilst those with small nuclei and a predominantly cribriform/micropapillary appearance did not stain and had a low TLI. In tumours of mixed histological pattern there was less concordance between staining and TLI. The significance of these findings in relation to the biological behaviour of these tumours and their clinical management is discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Amplification of the her-2/neu oncogene correlates with relapse and survival in human cancer. Science 235: 177–182, 1987
Barnes DM, Lammie GA, Millis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448–452, 1988
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Sutart SG, Udove J, Ullrich A, Press MF: Studies of the her-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
van de Vijver, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo type ductal carcinomain situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245, 1988
Bartkova J, Barnes DM, Millis RR, Gullick WJ: Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinomain situ. Human Pathol 21: 1164–1167, 1990
Venter DJ, Kumar S, Tuzi NL, Gullick WJ: Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistochemical assessment correlates with gene amplification. Lancet ii: 69–72, 1987
Meyer JS: Cell kinetics of histologic variants ofin situ breast carcinoma. Breast Cancer Res Treat 7: 171–180, 1986
Meyer JS, Connor RE:In vitro labelling of solid tissues with tritiated thymidine for autoradiographic detection of S-phase nuclei. Stain Technol 52: 185–195, 1977
Lammie GA, Barnes DM, Millis RR, Gullick WJ: An immunohistochemical study of the presence of c-erbB-2 protein in Paget's disease of the nipple. Histopathol 15: 505–514, 1989
Gullick WJ, Berger MS, Bennett PLP, Rothbard JB, Waterfield MD: Expression of c-erbB-2 protein in normal and transformed cells. Int J Cancer 40: 246–254, 1987
Meyer JS, Prey MU, Babcock DS, McDivitt RW: Breast carcinoma cell kinetics, morphology, stage, and host characteristics. A thymidine labelling study. Lab Invest 54: 41–51, 1986
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58: 453–457, 1988
Barnes DM: Breast cancer and a proto-oncogene: c-erbB-2 is a reliable prognostic marker. Br Med J 1061–1062, 1989
Silvestrini R, Daidone MG, Di Fronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of labelling index versus estrogen receptors and tumor size in node negative breast cancer. Breast Cancer Res Treat 7: 161–169, 1986
Meyer JS, Province M: Proliferative index of breast carcinoma by thymidine labelling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12: 191–204, 1988
Meyer JS, Coplin MD: Thymidine labelling index, flow cytometric S-phase measurement, and DNA index in human tumours. Am J Clin Pathol 89: 586–595, 1988
Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627–633, 1989
O'Reilly SM, Camplejohn RS, Barnes DM, Millis RR, Richards MA: DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 61: 671–674, 1990
O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Millis RR, Rubens RD, Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer (in press)
Shackney SE, Burholt DR, Pollice AA, Smith CA, Pugh RP, Hartsock RJ: Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumours. Cytometry 11: 94–104, 1990
Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 114: 160–163, 1990
Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 65: 1794–1800, 1990
Kommoss F, Colley M, Hart CE, Franklin WA:In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit. Mol Cell Probes 4: 11–23, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barnes, D.M., Meyer, J.S., Gonzalez, J.G. et al. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinomain situ . Breast Cancer Res Tr 18, 11–17 (1991). https://doi.org/10.1007/BF01975438
Issue Date:
DOI: https://doi.org/10.1007/BF01975438